Endocrine treatment of transsexuals: assessment of cardiovascular risk factors

@article{Nakatsuka2010EndocrineTO,
  title={Endocrine treatment of transsexuals: assessment of cardiovascular risk factors},
  author={Mikiya Nakatsuka},
  journal={Expert Review of Endocrinology \& Metabolism},
  year={2010},
  volume={5},
  pages={319 - 322}
}
  • M. Nakatsuka
  • Published 1 May 2010
  • Medicine
  • Expert Review of Endocrinology & Metabolism
Gender identity disorder (GID) is characterized by strong and persistent cross-gender identification and by persistent discomfort with one’s anatomical sex. Transsexualism is considered to be the extreme end of the spectrum of GID, which is characterized by a pursuit of sex reassignment surgery. The recent information on the prevalence of the transsexual end of the GID spectrum from The Netherlands is one in 11,900 males and one in 30,400 females [101], although biological mechanisms of GID are… 
3 Citations

Altered arterial stiffness in male‐to‐female transsexuals undergoing hormonal treatment

Evaluated arterial stiffness in MTF transsexuals undergoing hormonal treatment with and without progestin through a variety of routes is evaluated.

References

SHOWING 1-10 OF 17 REFERENCES

Endocrine treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective.

These guidelines are structured to provide evidence-based suggestions or, where evidence is lacking, expert recommendations on diagnostic procedures and hormonal treatment in adolescent and adult transsexuals, including long-term care and eligibility for surgery.

Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.

This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence, which was low or very low.

Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.

Cross-sex hormone treatment of transsexuals seems acceptably safe over the short and medium term, but solid clinical data are lacking.

Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.

It is concluded that cross-sex hormone treatment of male-to-female transsexuals using GnRHa and oestradiol-17beta valerate is effective, and side effects and complication rates can be reduced using the treatment regimen presented here.

The sudden and unexpected death of a female-to-male transsexual patient.

Association study of gender identity disorder and sex hormone-related genes

Testosterone decreases adiponectin levels in female to male transsexuals.

T can significantly reduce adiponectin serum levels in transsexual female patients, and high-density lipoprotein cholesterol decreased significantly, whereas body mass index, waist circumference and lean body mass increased significantly after 6 months of T treatment.

Hormonal therapy and sex reassignment: a systematic review and meta‐analysis of quality of life and psychosocial outcomes

The prognosis of individuals with gender identity disorder (GID) receiving hormonal therapy as a part of sex reassignment in terms of quality of life and other self‐reported psychosocial outcomes is assessed.